Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose
- 30 April 2002
- journal article
- abstracts
- Published by Elsevier BV in Journal of Hepatology